• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Report Finds Significant Industry Affiliation in IGWG ‘NGO’ Comments

08/11/2007 by Kaitlin Mara for Intellectual Property Watch Leave a Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

By Kaitlin Mara for Intellectual Property Watch
As negotiators gather at the United Nations this week in Geneva to seek ways to boost innovation on neglected diseases disproportionately affecting poor people, a new study was released showing that commentators at the negotiation’s public hearing came primarily from organisations affiliated in some way with the pharmaceutical or biotechnology industries.

The study, released on 7 November, was conducted by US non-governmental group Essential Action via survey. Commentators registered as an ‘NGO’, ‘Civil Society Group’, or ‘International Organization’ and were asked whether their group accepts donations from for-profit corporations or trade associations, and then asked for details regarding specific companies, amounts donated, and stated purpose of donations. Essential Action also independently researched funding sources and affiliations of commentators who did not respond to the survey.

The results of the study were released during the World Health Organization Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (IGWG), which is meeting from 5 to 10 November.

Overall in the study, Essential Action found twenty-two of the comments submitted by NGO/Civil Society groups were from organisations that had either received money from pharmaceutical corporations or had representatives from the industry on their board of directors. The level of involvement ranged from fairly minimal – the Colorado Chapter of the National Association of Hispanic Nurses, for instance, had accepted funding for its 2007 conference from several pharmaceutical and biotechnology firms -to fairly in-depth – the Alliance for Health Education and Development, for instance is headed by a former health care industry lobbyist. An additional thirteen trade associations with overt ties to the pharmaceutical industry joined in the IGWG comments. Only eight organisations listed as NGOs showed no ties with industry, though there were also eight academics with no apparent industry ties who commented.

Reactions to Essential Action’s survey were also mixed. Essential Action suggested that ties to industry are a helpful way to assess the value of comments from contributors: clearly those with a strong financial stake in the IGWG outcome are more subject to bias.

Among survey respondents who said they did not accept donations from for-profit corporations, there was some agreement with EA’s position. Thomas Pogge from Incentives for Global Health noted that it “was clear from many… contributions” that industry donations were being accepted and thanked Essential Action for its record-keeping. There was also disagreement, notably from Lawrence Kogan from the Institute for Trade, Standards and Sustainable Development, which advocates strong intellectual property regimes, felt that “to the extent there are corporate monies donated to support our efforts, all the better.”

Others admitted accepting for-profit monies but did not believe it affected their ability to deliver honest, qualified opinions. Virginia T. Ladd of the American Autoimmune Related Diseases Association noted that it “is standard practice in the USA [to] receive corporate and foundation funds from those entities [with] an interest in the work.”

Robert Weissman of Essential Action said in a statement: “Understanding an organisation’s ties is helpful in assessing the merits of comments submitted.”

Kaitlin Mara may be reached at info@ip-watch.ch.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"Report Finds Significant Industry Affiliation in IGWG ‘NGO’ Comments" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: News, Biodiversity/Genetic Resources/Biotech, English, Health & IP, Human Rights, Lobbying, North America, Patents/Designs/Trade Secrets, Technical Cooperation/ Technology Transfer, United Nations - other, WHO

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2025 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.